U.S. flag

An official website of the United States government

NM_000030.3(AGXT):c.1079G>A (p.Arg360Gln) AND not provided

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jan 25, 2024
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001857592.14

Allele description [Variation Report for NM_000030.3(AGXT):c.1079G>A (p.Arg360Gln)]

NM_000030.3(AGXT):c.1079G>A (p.Arg360Gln)

Gene:
AGXT:alanine--glyoxylate aminotransferase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
2q37.3
Genomic location:
Preferred name:
NM_000030.3(AGXT):c.1079G>A (p.Arg360Gln)
HGVS:
  • NC_000002.12:g.240878721G>A
  • NG_008005.1:g.14977G>A
  • NM_000030.3:c.1079G>AMANE SELECT
  • NP_000021.1:p.Arg360Gln
  • NP_000021.1:p.Arg360Gln
  • NC_000002.11:g.241818138G>A
  • NM_000030.2:c.1079G>A
Protein change:
R360Q
Links:
dbSNP: rs180177161
NCBI 1000 Genomes Browser:
rs180177161
Molecular consequence:
  • NM_000030.3:c.1079G>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002234351Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Jan 25, 2024)
germlineclinical testing

PubMed (8)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis.

Hoppe B, Dittlich K, Fehrenbach H, Plum G, Beck BB.

Am J Kidney Dis. 2011 Sep;58(3):453-5. doi: 10.1053/j.ajkd.2011.05.012. Epub 2011 Jun 25.

PubMed [citation]
PMID:
21705122

Mutational Analysis of Agxt in Tunisian Population with Primary Hyperoxaluria Type 1.

M'dimegh S, Omezzine A, M'barek I, Moussa A, Mabrouk S, Kaarout H, Souche G, Chemli J, Aloui S, Aquaviva-Bourdain C, Achour A, Abroug S, Bouslama A.

Ann Hum Genet. 2017 Jan;81(1):1-10. doi: 10.1111/ahg.12178. Epub 2016 Dec 9.

PubMed [citation]
PMID:
27935012
See all PubMed Citations (8)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002234351.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (8)

Description

This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 360 of the AGXT protein (p.Arg360Gln). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individuals with primary hyperoxaluria type I (PMID: 21705122, 27935012, 30341509, 33721035). ClinVar contains an entry for this variant (Variation ID: 204147). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AGXT protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects AGXT function (PMID: 19479957, 30341509). This variant disrupts the p.Arg360 amino acid residue in AGXT. Other variant(s) that disrupt this residue have been observed in individuals with AGXT-related conditions (PMID: 25644115, 28893421), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 24, 2024